TITLE

Immune Responses to Mumps Vaccine in Adults Who Were Vaccinated in Childhood

AUTHOR(S)
Hanna-Wakim, Rima; Yasukawa, Linda L.; Sung, Phillip; Arvin, Ann M.; Gans, Hayley A.
PUB. DATE
June 2008
SOURCE
Journal of Infectious Diseases;6/15/2008, Vol. 197 Issue 12, p1669
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. In a mumps outbreak in the United States, many infected individuals were adults who had received 2 doses of mumps vaccine. The persistence of cellular immunity to mumps vaccine has not been defined. Methods. This was an observational, nonrandomized cohort study evaluating cell-mediated and humoral immunity to mumps in 10 vaccinated and 10 naturally immune adults. Mumps-specific T cell activation and interferon (IFN)-γ production were measured using lymphoproliferative and flow cytometry assays, and mumps immunoglobulin (Ig) G was measured using enzyme-linked immunosorbent assay. Results. T cell immunity to mumps was high in both groups; 70% of vaccinated and 80% of naturally immune individuals had a positive (⩾3) stimulation index (SI) (P = 1.0). The mean percentages of mumps-specific CD4+ T cells that expressed CD69 and produced IFN-γ were equivalent in the 2 groups: 0.06% and 0.12%, respectively (P = .11). The mean SIs in the groups were also equivalent, although IFN-γ concentrations from cultures stimulated with mumps antigen were higher in naturally immune adults than in vaccinated adults (P ⩽ .01). All adults were positive for mumps IgG. Conclusion. T and B cell immunity to mumps was detected in adults at least 10 years after immunization. Except for IFN-γ release, responses in vaccinated adults paralleled those observed in naturally immune individuals.
ACCESSION #
32586563

 

Related Articles

  • Age-related waning of in vitro Interferon-γ levels against r32kDaBCG in BCG vaccinated children. Anuradha, B.; Santosh, C. M.; Priya, V. Hari Sai; Latha, G. Suman; Murthy, K. J. R.; Lakshmi, Valluri Vijaya // Journal of Immune Based Therapies & Vaccines;2007, Vol. 5, p1 

    Background: Mycobacterium bovis BCG vaccine has displayed inconsistent efficacy in different trials conducted in various geographical regions. Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries. Many...

  • Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. Weinberg, Adriana; Zhang, Jane H.; Oxman, Michael N.; Johnson, Gary R.; Hayward, Anthony R.; Caulfield, Michael J.; Irwin, Michael R.; Clair, James; Smith, Jeffrey G.; Stanley, Harold; Marchese, Rocio D.; Harbecke, Ruth; Williams, Heather M.; Chan, Ivan S. F.; Arbeit, Robert D.; Gershon, Anne A.; Schödel, Florian; Morrison, Vicki A.; Kauffman, Carol A.; Straus, Steve E. // Journal of Infectious Diseases;10/1/2009, Vol. 200 Issue 7, p1068 

    Background. The objectives of this study were to evaluate the association between varicella-zoster virus (VZV)— specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ morbidity and to compare immune responses to HZ and zoster vaccine. Methods. In...

  • Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. Levin, M. J.; Oxman, M. N.; Zhang, J. H.; Johnson, G. R.; Stanley, H.; Hayward, A. R.; Caulfield, M. J.; Irwin, M. R.; Smith, J. G.; Clair, J.; Chan, I. S. F.; Williams, H.; Harbecke, R.; Marchese, R.; Straus, S. E.; Gershon, A.; Weinberg, A. // Journal of Infectious Diseases;3/15/2008, Vol. 197 Issue 6, p825 

    Background. A double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific...

  • Long-Lasting T Cell Responses to Biological Warfare Vaccines in Human Vaccinees. Allen, Jennifer S.; Skowera, Ania; Rubin, G. James; Wessely, Simon; Peakman, Mark // Clinical Infectious Diseases;7/1/2006, Vol. 43 Issue 1, p1 

    Background. Medical countermeasures against biological warfare include the use of vaccines for anthrax and plague, which require repeated dosing and adjuvant to achieve adequate protection from threats such as inhalational anthrax and pneumonic plague. Despite the widespread use of these...

  • Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Mikoluc, B.; Kayhty, H.; Bernatowska, E.; Motkowski, R. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2008, Vol. 27 Issue 10, p923 

    The aim of the study was to determine the concentration of pneumococcal antibodies after a dose of 7-valent pneumococcal conjugate vaccine (PCV7) in 30 asplenic children between 4 months and 19 years of age. Fifteen children had received pneumococcal polysaccharide vaccine (PPV) approximately 5...

  • Immune Response of Cytotoxic T Lymphocytes and Possibility of Vaccine Development for Hepatitis C Virus Infection. Hiroishi, Kazumasa; Eguchi, Junichi; Ishii, Shigeaki; Hiraide, Ayako; Sakaki, Masashi; Doi, Hiroyoshi; Omori, Risa; Imawari, Michio // Journal of Biomedicine & Biotechnology;2010, p1 

    Immune responses of cytotoxic T lymphocytes (CTLs) are implicated in viral eradication and the pathogenesis of hepatitis C. Weak CTL response against hepatitis C virus (HCV) may lead to a persistent infection. HCV infection impairs the function of HCV-specific CTLs; HCV proteins are thought to...

  • Age-Dependent Differences in IgG Isotype and Avidity Induced by Measles Vaccine Received during the First Year of Life. Nair, Nitya; Gans, Hayley; Lew-Yasukawa, Linda; Long-Wagar, Andrea C.; Arvin, Ann; Griffin, Diane E. // Journal of Infectious Diseases;11/1/2007, Vol. 196 Issue 9, p1339 

    Background. Measles remains an important cause of death worldwide, and vaccinating individuals at an earlier age could lead to better control of the disease. However, persistence of maternal antibody and young age affect the quantity of vaccine-induced neutralizing antibody and may also affect...

  • Effect of the Novel Influenza A (H1N1) Virus in the Human Immune System. Giamarellos-Bourboulis, Evangelos J.; Raftogiannis, Maria; Antonopoulou, Anastasia; Baziaka, Fotini; Koutoukas, Pantelis; Savva, Athina; Kanni, Theodora; Georgitsi, Marianna; Pistiki, Aikaterini; Tsaganos, Thomas; Pelekanos, Nikolaos; Athanassia, Sofia; Galani, Labrini; Giannitsioti, Efthymia; Kavatha, Dimitra; Kontopidou, Flora; Mouktaroudi, Maria; Poulakou, Garyfallia; Sakka, Vissaria; Panagopoulos, Periklis // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    Background: The pandemic by the novel H1N1 virus has created the need to study any probable effects of that infection in the immune system of the host. Methodology/Principal Findings: Blood was sampled within the first two days of the presentation of signs of infection from 10 healthy...

  • IMMUNE RESPONSES OF GOATS (SHAMI BREED) TO VACCINATION WITH A FULL, REDUCED AND CONJUNCTIVAL DOSE OF BRUCEVAC (BRUCELLA MELITENSIS REV.1) VACCINE. Aldomy, F.; Alkhawaldeh, M.; Younis, Andi B. // Pakistan Veterinary Journal;2009, Vol. 29 Issue 4, p149 

    Three groups of Shami goats were randomly vaccinated with Brucevac (Rev. 1) vaccine. Group 1 was vaccinated subcutaneously with a full dose (1.54 x 109 organisms). Group 2 was vaccinated conjunctively with one eye drop (5.2 x 108 organisms), while Group 3 was injected subcutaneously with a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics